# Advances of Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma

## TL;DR

This paper reviews the treatment of a rare and aggressive lung cancer called large cell neuroendocrine carcinoma, focusing on new insights from molecular subtypes and immune checkpoint inhibitors.

## Contribution

The paper provides a comprehensive overview of recent advances in molecular subtyping and immunotherapy for LCNEC.

## Key findings

- Molecular subtyping using next-generation sequencing helps guide treatment decisions for LCNEC.
- Immune checkpoint inhibitors show promise but are based on limited retrospective studies and case reports.
- Current treatment strategies for LCNEC are largely borrowed from small and non-small cell lung cancer.

## Abstract

肺大细胞神经内分泌癌（large cell neuroendocrine carcinoma, LCNEC）是一种罕见且高度侵袭性的高级别神经内分泌癌，患者确诊时分期偏晚，预后差，其治疗策略多借鉴小细胞肺癌和非小细胞肺癌的方案。近年来，二代测序技术为LCNEC的精准分型提供了理论基础，研究也证实了不同LCNEC亚型与化疗方案疗效之间的关联性。免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）的应用，为LCNEC患者提供了新的治疗选择，但相关数据仅见于小样本的回顾性研究和少量个案报道。本文回顾了LCNEC的流行病学特征和经典治疗策略，并针对LCNEC的分子亚型研究进展和ICIs的应用进展进行综述，为临床治疗提供新思路。

Summary of available studies on ICIs in LCNEC